Influenza News and Research

Latest Influenza News and Research

Viewpoints: The 'real story' of Ryan at AARP; 'Get thee to an emergency room'

The headlines this weekend were all about the boos Paul Ryan elicited on Friday when he addressed the AARP, the self-styled seniors' lobby. The herd of independent media minds missed the real story, which is that the Republican Vice Presidential nominee went into the heart of the entitlement culture, told some hard truths, and even won applause for doing so.

26 Sep 2012

UC Medicine nurses to administer free flu shots to licensed taxicab drivers at O'Hare Midway

As part of an initiative to vaccinate some of Chicago's most vulnerable populations, University of Chicago Medicine nurses will administer free flu shots to licensed taxicab drivers at O'Hare International Airport on Tuesday, Sept. 25, and at Midway International Airport the following Tuesday, Oct. 2. Up to 1,000 cabbies could be vaccinated over the two days.

25 Sep 2012

Biologists unravel why some people infected with HIV have more virus

Biologists at UC San Diego have unraveled the anti-viral mechanism of a human gene that may explain why some people infected with HIV have much higher amounts of virus in their bloodstreams than others.

24 Sep 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Study uncovers why some HIV-positive people take long time to progress to full-blown AIDS

One of the big mysteries of AIDS is why some HIV-positive people take more than a decade to progress to full-blown AIDS, if they progress at all.

20 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Immune Targeting Systems Limited, an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus.

18 Sep 2012

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way.

17 Sep 2012

SLU study: Many U.S. schools not prepared for bioterrorism attacks, outbreaks of pandemics

Many U.S. schools are not prepared for bioterrorism attacks, outbreaks of emerging infectious diseases or pandemics, despite the recent 2009 H1N1 influenza pandemic that resulted in more than 18,000 deaths worldwide, Saint Louis University researchers say.

15 Sep 2012

Research roundup: Patients' experiences at safety-net hospitals

Each week KHN reporter Ankita Rao compiles a selection of recently released health policy studies and briefs.

15 Sep 2012

Pam2Cys nasal spray may be useful agent against pandemics and emerging viral strains

In an advance toward development of a nasal spray that protects against infection with influenza and spread of the disease, scientists are reporting identification of a substance that activates the first-line defense system against infection inside the nose. They describe effects of a synthetic form of a natural substance found in bacterial cell walls in ACS' journal Molecular Pharmaceutics.

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Individuals without capacity excluded from potentially beneficial trials

Individuals who lack the capacity to consent to taking part in clinical trials could be missing out on the opportunity to receive potentially beneficial interventions, shows UK research.

11 Sep 2012

Pfizer, Visterra collaborate to discover novel antibodies

Visterra Inc., developer of novel therapeutics to treat major diseases, announced today that it has entered into a collaboration agreement with Pfizer to discover novel antibodies using Visterra's proprietary platform.

11 Sep 2012

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced it has been awarded a contract by the United States (U.S.) Department of Health and Human Services to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

11 Sep 2012

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9.

10 Sep 2012

Dynamic mapping could potentially help fill gaps in influenza research

Influenza outbreaks in the United States typically begin with the arrival of cold weather and then spread in seasonal waves across geographic zones. But the question of why epidemics can vary from one season to the next has baffled scientists.

10 Sep 2012

New cell screening method can identify potential anti-influenza drugs

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs.

6 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Influenza News and Research

Latest Influenza News and Research

Viewpoints: The 'real story' of Ryan at AARP; 'Get thee to an emergency room'

UC Medicine nurses to administer free flu shots to licensed taxicab drivers at O'Hare Midway

Biologists unravel why some people infected with HIV have more virus

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

Study uncovers why some HIV-positive people take long time to progress to full-blown AIDS

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

SLU study: Many U.S. schools not prepared for bioterrorism attacks, outbreaks of pandemics

Research roundup: Patients' experiences at safety-net hospitals

Pam2Cys nasal spray may be useful agent against pandemics and emerging viral strains

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Individuals without capacity excluded from potentially beneficial trials

Pfizer, Visterra collaborate to discover novel antibodies

CSL Biotherapies receives U.S. Government contract to supply pandemic vaccine antigens

New oral antiseptic spray effective in killing 99.9% of infectious airborne germs

Dynamic mapping could potentially help fill gaps in influenza research

New cell screening method can identify potential anti-influenza drugs

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Strong antiviral antibody response observed in oral administration of Flucide

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Influenza News and Research

Latest Influenza News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in